Budd-Chiari syndrome is a rare and potentially life-threatening clinical disorder defined by the obstruction of hepatic venous outflow at any level between the small intrahepatic veins and the junction of the inferior vena cava with the right atrium ^1,3. Obstruction blocks the egress of blood from the hepatic parenchyma, triggering a rapid cascade of sinusoidal congestion, postsinusoidal portal hypertension, ischemic centrilobular hepatocyte injury, and parenchymal extinction ^3,4. In Western populations, the disease is predominantly caused by acquired or inherited prothrombotic risk factors, with myeloproliferative neoplasms representing the single most frequent underlying etiology ^3,5. Conversely, in Asian and developing regions, inferior vena cava membranous webs and ostial stenoses are significantly more prevalent ⁶. Clinical manifestations range from completely asymptomatic incidental findings discovered on cross-sectional imaging to fulminant hepatic failure characterized by multi-organ dysfunction ^4,7. Prompt diagnosis utilizing color Doppler ultrasonography and multi-detector computed tomography, coupled with immediate therapeutic anticoagulation and a stepwise interventional strategy, is essential to restore hepatic venous drainage and ensure long-term survival ^4,5.

Etiology & Risk Factors

Myeloproliferative Neoplasms: The most common underlying prothrombotic cause, accounting for over 40% to 50% of cases ^3,5. The JAK2 V617F mutation must be actively investigated even in the absence of peripheral blood cytosis, as occult polycythemia vera or essential thrombocythemia frequently presents solely as hepatic vein thrombosis.
Inherited Thrombophilias: Factor V Leiden mutation, prothrombin gene G20210A mutation, protein C deficiency, protein S deficiency, antithrombin III deficiency, and antiphospholipid syndrome ^1,4. Almost half of all patients possess multiple concurrent prothrombotic risk factors ³.
Acquired Hypercoagulable States: Paroxysmal nocturnal hemoglobinuria (PNH), inflammatory bowel disease, Behcet disease, chronic infections, and pregnancy or the postpartum period ^1,4.
Exogenous Hormones & Medications: Oral contraceptive pill (OCP) usage and estrogen-containing hormone replacement therapies ⁴.
Anatomical and Mechanical Factors: Inferior vena cava (IVC) webs, congenital caval membranes, benign or malignant tumors (e.g., hepatocellular carcinoma, renal cell carcinoma, adrenal tumors) causing direct vascular invasion or extrinsic compression, and trauma or abdominal infections leading to retroperitoneal fibrosis ^1,6.

Pathophysiology

The core pathophysiological mechanism of Budd-Chiari syndrome involves mechanical or thrombotic occlusion of hepatic venous drainage, leading immediately to a marked elevation in sinusoidal pressure ^1,7. As outflow is impeded, hepatic blood flow stagnates, causing profound centrilobular congestion, hypoxia, and ischemic necrosis of hepatocytes surrounding the central veins ^3,4. Increased sinusoidal hydrostatic pressure forces protein-rich lymph to weep across the liver capsule into the peritoneal cavity, resulting in massive, high-serum-ascites albumin gradient (SAAG) ascites ⁴. To compensate for the obstruction of the right, middle, and left hepatic veins, the caudate lobe—which possesses independent venous drainage directly into the retrohepatic inferior vena cava via small separate ostia—hypertrophies dramatically from preserved perfusion ^1,3. This caudate hypertrophy exerts extrinsic mass effect upon the already compressed main hepatic veins and the inferior vena cava, worsening the outflow block and accelerating the transition toward chronic postsinusoidal portal hypertension, congestive cirrhosis, and regenerative nodular hyperplasia ^4,7.

Clinical Presentation & Classic Clinical Signs

History & Cardinal Symptoms: The clinical presentation is notoriously heterogeneous, varying from subclinical presentations to fulminant hepatic failure ^3,4. Typical symptomatic patients present subacutely with progressive abdominal distension secondary to tense ascites, dull right upper quadrant or epigastric pain caused by stretching of Glisson's capsule, nausea, anorexia, and lower extremity edema if the inferior vena cava is obstructed ^1,4. Acute presentations feature sudden, excruciating abdominal pain, rapidly progressive jaundice, and acute liver failure with encephalopathy, whereas chronic forms mimic decompensated cirrhosis ^4,7.
Physical Examination & Named Clinical Signs: Physical examination frequently reveals tender hepatomegaly with a smooth, firm liver edge, prominent abdominal wall collateral veins indicating inferior vena cava or portal decompression, shifting dullness and fluid thrill confirming massive ascites, and peripheral pitting edema up to the thighs or genitalia due to elevated inferior vena cava pressure ^1,4. Jaundice is generally mild unless the patient presents with fulminant disease or advanced secondary biliary cirrhosis ⁴.

Diagnostic Workup & Interpretation (Laboratory, Imaging & ECG/Pathology)

Diagnostic Modality / Test	Expected Clinical & Radiological / Laboratory Finding
Gold-Standard Investigation	Hepatic venography combined with direct pressure manometry demonstrating outflow block, web formation, or non-visualization of hepatic veins alongside a hepatic venous pressure gradient (HVPG) exceeding normal limits ^1,4.
Laboratory Panel	Elevated serum aminotransferases (AST, ALT) in acute phases, variable increases in alkaline phosphatase and gamma-glutamyl transferase (GGT), hyperbilirubinemia, and hypoalbuminemia with prolonged prothrombin time (INR) in advanced disease ^1,3. Coagulation and thrombophilia screening must include testing for JAK2 V617F mutation, protein C, protein S, antithrombin, factor V Leiden, lupus anticoagulant, and flow cytometry for paroxysmal nocturnal hemoglobinuria ^1,5.
Imaging / Radiology (X-ray, US, CT, MRI)	Color Doppler Ultrasound is the essential initial diagnostic test, revealing absent, attenuated, or reversed flow in the hepatic veins, intrahepatic collateral bridging veins ("spiderweb" pattern), thrombosis within the lumens, and marked hypertrophy of the caudate lobe ^3,5. Contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) demonstrates heterogeneous enhancement of the liver parenchyma during the arterial phase (hypervascular peripheral areas with hypovascular congested areas) and persistent delayed enhancement, alongside visualization of IVC stenosis or caval thrombus ^3,7.
ECG / Histopathology / Procedural	Histopathological analysis of transjugular liver biopsy specimens displays marked centrilobular congestion, sinusoidal dilation, hemorrhage, red cell extravasation, parenchymal extinction, and perisinusoidal fibrosis without primary biliary duct damage ^1,4. Electrocardiogram is performed for general pre-procedural and pre-transplant cardiac clearance ⁴.

Staging, Classification & Clinical Scoring Systems

Criterion / Stage / Score Component	Clinical Threshold, Points & Management Implication
Clichy Prognostic Score	Incorporates age, Child-Pugh class, and ascites severity. A prognostic index dividing patients into risk strata to determine the absolute necessity and timing for emergency transjugular intrahepatic portosystemic shunt (TIPS) or orthotopic liver transplantation ^4,5.
Rotterdam Scoring System	Utilizes parameters including encephalopathy, ascites, prothrombin time (INR), and serum bilirubin levels. Designed to predict survival without liver transplantation, guiding whether medical therapy and shunting are sufficient or if immediate transplant listing is mandatory ^4,5.
Anatomical Classification	Categorizes obstruction site into Type I (IVC occlusion alone with patent hepatic veins), Type II (hepatic vein thrombosis alone), Type III (diffuse occlusion of both hepatic veins and IVC), and segmental hepatic vein ostial stenosis ^1,6. Guides technical selection between angioplasty, stenting, TIPS, or surgical shunting ^4,6.

Differential Diagnosis

Differential Condition	Distinguishing Clinical, Biochemical & Imaging Features
Cirrhosis of Etiologies Other Than Vascular	Presents with shrunken liver, nodular contour, and normal patent hepatic veins and inferior vena cava on Doppler ultrasound; absence of isolated caudate lobe hypertrophy out of proportion to right lobe atrophy ^1,3.
Sinusoidal Obstruction Syndrome (VOD)	History of bone marrow transplantation, exposure to pyrrolizidine alkaloids, or chemotherapy. Characterized by obliterative endophlebitis of terminal hepatic venules with patent main hepatic veins on Doppler imaging ^1,4.
Right-Sided Heart Failure / Constrictive Pericarditis	Features elevated jugular venous pressure, prominent X and Y descents, dependent peripheral edema, hepatomegaly with pulsatile liver, and normal patent hepatic veins with dilation secondary to backward cardiac pressure rather than intrinsic venous thrombosis ^1,4.
Fulminant Viral or Drug-Induced Hepatitis	Marked transaminase elevations exceeding 1,000 IU/L with acute hepatic failure symptoms, in the presence of normal hepatic venous outflow anatomy and patent vasculature on Doppler evaluation ^4,7.

Management & Treatment Protocol

Initial Stabilization & Resuscitation: Admission to a specialized hepatology or vascular liver disease unit ⁵. Management of refractory ascites via strict sodium restriction (dietary sodium < 2 g/day), targeted loop diuretics (spironolactone 100–400 mg daily combined with furosemide 40–160 mg daily), and large-volume therapeutic paracentesis with intravenous albumin replacement (8 g per liter of fluid removed) if paracentesis exceeds 5 liters ^1,4. Prophylaxis against variceal hemorrhage via screening endoscopy and non-selective beta-blockers or endoscopic band ligation ^4,5.
First-Line Medical / Pharmacological Therapy (with exact adult dosing): Lifelong therapeutic anticoagulation is the cornerstone of management and must be initiated immediately upon diagnosis unless absolute contraindications exist ^3,4. Administer low-molecular-weight heparin (LMWH), such as enoxaparin at a therapeutic dose of 1 mg/kg subcutaneously every 12 hours (or tinzaparin 175 IU/kg subcutaneously once daily), bridged rapidly to oral vitamin K antagonists (warfarin) titrated to maintain a strict target international normalized ratio (INR) of 2.0 to 3.0, or direct oral anticoagulants (DOACs) under specialist guidance when etiology is verified ^1,4,5. Concurrently treat the underlying prothrombotic condition (e.g., cytoreductive therapy like hydroxyurea for underlying myeloproliferative neoplasms to maintain hematocrit < 45% and platelet count within target ranges) ^1,3.
Surgical / Interventional Indications: Transjugular intrahepatic portosystemic shunt (TIPS) placement is indicated when medical therapy fails to control ascites, liver function progressively deteriorates, or portal hypertension complications persist ^4,5. Percutaneous balloon angioplasty with or without metallic stent placement is the treatment of choice for short-segment hepatic vein stenosis or membranous obstruction of the inferior vena cava ^4,6. Surgical portosystemic shunts (e.g., mesocaval or portocaval shunts) are reserved for cases where TIPS is technically unfeasible or fails ⁴. Orthotopic liver transplantation is preserved for patients presenting with fulminant hepatic failure, those who develop end-stage liver failure despite successful recanalization, or when shunt procedures and interventional radiology fail ^4,7.

Complications & Prognosis

Complications: Progression to end-stage congestive cirrhosis, refractory ascites, spontaneous bacterial peritonitis, bleeding esophageal or gastric varices, hepatic encephalopathy, acute-on-chronic liver failure, and extension of thrombosis into the portal venous system (mesenteric or portal vein thrombosis) ^1,4.
Prognosis: With modern stepwise management combining early therapeutic anticoagulation, aggressive interventional radiology (angioplasty and TIPS), and liver transplantation when necessary, the overall 5-year survival rate exceeds 80% to 85% in specialized vascular liver disease centers ^4,5. Unrecognized and untreated acute cases carry a near 90% mortality rate within three years, typically culminating in liver failure, sepsis, or massive variceal hemorrhage ^4,7.

Medipaedia.org

Budd-Chiari syndrome